Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.

One potential avenue for future cancer therapy involves the specific targeting of effector genes to cancer cells throughout the body, including distant metastatic sites. As a first step toward this goal, we tested the ability of the transcriptional regulatory elements of the human and mouse tyrosinase genes to promote high levels of pigment cell-specific transcription. A construct consisting of 209 bp of the human tyrosinase promoter linked to two enhancer elements was demonstrated to drive high-level, melanoma-specific expression of a beta-galactosidase (beta-gal) reporter gene in transient transfection assays. In studies of the murine tyrosinase promoter region, constructs containing up to 2500 bp of the 5' regulatory region were found to have very low transcriptional activity in murine melanoma cells. However, as with the human system, addition of two tandem repeats of an upstream enhancer element resulted in high levels of lineage-specific transcriptional activation. The murine tyrosinase promoter-enhancer expression cassette was introduced into the E1 region of a recombinant adenovirus to generate the virus AdmTyr-beta gal. This virus grows to high titer and maintains transcriptional specificity for pigment cell lineages. Strikingly, AdmTyr-beta gal is extremely active in human melanoma cells, in some cases exceeding the transcriptional activity of a cytomegalovirus promoter-driven recombinant beta-gal virus. Tissue specificity of gene expression is maintained, with very low levels observed in tumors and primary human cells derived from other lineages. These data provide evidence that it is possible to target human melanoma cells with great efficiency and specificity using high-titer recombinant adenovirus vectors.

[1]  Hiroaki,et al.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. , 1996, Cancer research.

[2]  Hart Ir.  Tissue specific promoters in targeting systemically delivered gene therapy. , 1996 .

[3]  Ronald G. Crystal,et al.  Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.

[4]  M. Zoppè,et al.  Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Richards,et al.  Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. , 1995, Human gene therapy.

[6]  S. Nagataki,et al.  Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. , 1995, Cancer research.

[7]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  X. -. Chen,et al.  Combination gene therapy for liver metastasis of colon carcinoma in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Shibahara,et al.  Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene , 1994, Molecular and cellular biology.

[10]  R. Vile,et al.  Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. , 1994, Cancer research.

[11]  K. Calame,et al.  The basic helix-loop-helix-zipper domain of TFE3 mediates enhancer-promoter interaction , 1994, Molecular and cellular biology.

[12]  C. Goding,et al.  Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator , 1994, Molecular and cellular biology.

[13]  Y. Kan,et al.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. , 1994, Science.

[14]  G. Schütz,et al.  The mouse tyrosinase gene. Promoter modulation by positive and negative regulatory elements. , 1994, The Journal of biological chemistry.

[15]  James A. Vaught,et al.  microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. , 1994, Genes & development.

[16]  Andrew P. Read,et al.  Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene , 1994, Nature Genetics.

[17]  I. Kawase,et al.  Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. , 1994, Cancer research.

[18]  H. Fine,et al.  Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. , 1994, Cancer research.

[19]  F. Graham,et al.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Monaghan,et al.  A cell‐specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number‐related expression in transgenic mice. , 1994, The EMBO journal.

[21]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[22]  U. Yavuzer,et al.  Melanocyte-specific gene expression: role of repression and identification of a melanocyte-specific factor, MSF , 1994, Molecular and cellular biology.

[23]  B. Kwon,et al.  Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. , 1994, The Journal of investigative dermatology.

[24]  J. Lingrel,et al.  A helix-loop-helix transcription factor-like gene is located at the mi locus. , 1993, The Journal of biological chemistry.

[25]  N. Jenkins,et al.  Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein , 1993, Cell.

[26]  R. Vile,et al.  In vitro and in vivo targeting of gene expression to melanoma cells. , 1993, Cancer research.

[27]  H. Yamamoto,et al.  Conserved regulatory mechanisms of tyrosinase genes in mice and humans. , 1992, Pigment cell research.

[28]  S. Shibahara,et al.  Identification of a cis-acting element that enhances the pigment cell-specific expression of the human tyrosinase gene. , 1992, The Journal of biological chemistry.

[29]  U. Yavuzer,et al.  Positive and negative elements regulate a melanocyte-specific promoter , 1992, Molecular and cellular biology.

[30]  S. Rosenberg,et al.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Hennighausen,et al.  The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. , 1991, Nucleic acids research.

[32]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[33]  C. Richards,et al.  Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Taylor‐Papadimitriou.  Report on the first international workshop on carcinoma‐associated mucins , 1991, International journal of cancer.

[35]  David Baltimore,et al.  Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo , 1991, Cell.

[36]  M. Klüppel,et al.  The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. Bosch,et al.  Rescue of the albino phenotype by introduction of a functional tyrosinase gene into mice. , 1990, The EMBO journal.

[38]  P. Leder,et al.  The cytomegalovirus enhancer: a pan-active control element in transgenic mice , 1990, Molecular and cellular biology.

[39]  H. Yamamoto,et al.  Melanization in albino mice transformed by introducing cloned mouse tyrosinase gene. , 1990, Development.

[40]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[41]  T. Shenk,et al.  The adenovirus type 5 E1A enhancer contains two functionally distinct domains: One is specific for E1A and the other modulates all early units in cis , 1986, Cell.

[42]  L. Old,et al.  GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody , 1982, The Journal of experimental medicine.

[43]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[44]  I. Hart.  Tissue specific promoters in targeting systemically delivered gene therapy. , 1996, Seminars in oncology.

[45]  井戸 章雄.  Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter , 1995 .

[46]  F. Higashino,et al.  Transcriptional regulation of the adenovirus E1A gene. , 1995, Current topics in microbiology and immunology.

[47]  D. Curiel,et al.  Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. , 1994, Human gene therapy.

[48]  R. Ganss,et al.  The Mouse Tyrosinase Gene , 2022 .